On 26 November, the ACSOSA Zona Nord association visited the VHIO facilities to present a cheque with the funds raised…
en_news
Co-led by Rodrigo Toledo and Elena Garralda, IMMUNOMICS-VHIO is a platform for the discovery and validation of liquid biopsy biomarkers…
Following the success of the VHIO Talks 2025 series, which was very well received by the public, VHIO has decided…
Biopharmaceutical company Oniria Therapeutics, Vall d’Hebron Institute of Oncology (VHIO) and Institut Català d’Investigació Química (ICIQ) will work together on…
Promoted by SOLTI and developed in scientific collaboration with the Vall d’Hebron Institute of Oncology (VHIO), the SOLTI-1910 RADIOLA study…
The Phase 2 clinical trial PremiÈRe (SOLTI-2104) is the first to evaluate the oral drug elacestrant -either alone or combined…
During August, Clàudia Gracia contacted the Vall d’Hebron Institute of Oncology (VHIO) to share her intention to launch a charitable…
On November 5 and 6, during the SEOR 2025 symposium, the General Assembly of the Spanish Society of Radiation Oncology…
Dr. Francisco Martínez-Jiménez, Head of the Computational Immunogenomics Group at VHIO, has been awarded a Consolidator Grant from the European…
Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy…
